-
Neuland Laboratories Announces Launch of Venlafaxine Extended-Release Tablets
Neuland Laboratories Limited, a leading pharmaceutical company, announced the launch of Venlafaxine Extended-Release Tablets, a generic version of Effexor XR® (venlafaxine HCl) Extended-Release Tablets.
-
Neuland Laboratories Receives US FDA Approval for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Tablets
Neuland Laboratories Limited announced that it has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Tablets, 150 mg and 300 mg.
-
Neuland Laboratories Files ANDA for Gemifloxacin Mesylate Tablets in the US
Neuland Laboratories Limited announced that it has filed an Abbreviated New Drug Application (ANDA) with the United States Food and Drug Administration (US FDA) for Gemifloxacin Mesylate Tablets, 320 mg.
-
Neuland Announces the Submission of 1st ANDA for Syrup Formulation
Neuland Laboratories Limited (Neuland), a leading global pharmaceutical company, today announced the submission of its first Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA), for a Syrup formulation.
-
Neuland Receives US FDA Approval for Generic Version of Rifaximin Tablets USP, 200 mg
Neuland Laboratories Limited (Neuland), a leading global pharmaceutical company, today announced that it has received approval from the United States Food and Drug Administration (US FDA) for its ANDA Rifaximin Tablets USP, 200 mg.
-
Neuland Receives US FDA Approval for Generic Version of Vancomycin Hydrochloride Injection, USP
Neuland Laboratories Limited (Neuland), a leading global pharmaceutical company, today announced that it has received approval from the United States Food and Drug Administration (US FDA) for its ANDA Vancomycin Hydrochloride Injection, USP.
-
Neuland Labs Q3 net profit tanks 65% on lower sales, higher R&D costs
Pharmaceutical company Neuland Laboratories reported a sharp 65% decline in consolidated net profit for the quarter ended December 2023, hit by lower sales and higher research and development (R&D) costs.
-
Neuland Labs gets USFDA nod for generic version of Merck's Januvia
Pharmaceutical firm Neuland Laboratories has received final approval from the US Food and Drug Administration (USFDA) to market a generic version of Merck & Co's diabetes drug Januvia (sitagliptin phosphate) in the United States.
-
Neuland Labs launches generic version of Sanofi's Lantus in India
Neuland Laboratories has launched a generic version of Sanofi's Lantus (insulin glargine) in India, the company said in a statement.
-
Neuland Laboratories Receives US FDA Approval for Budesonide Inhalation Aerosol
Neuland Laboratories Limited, a global pharmaceutical company, announced today that it has received final approval from the United States Food and Drug Administration (US FDA) for its Budesonide Inhalation Aerosol.
-
Neuland Laboratories Enters into Strategic Partnership with Xeris Pharmaceuticals
Neuland Laboratories Limited, a global pharmaceutical company, today announced that it has entered into a strategic partnership with Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company dedicated to addressing unmet medical needs.
-
Neuland Laboratories Reports Strong Financial Results for Q3 FY23
Neuland Laboratories Limited, a global pharmaceutical company, today announced its financial results for the third quarter ended December 31, 2022.
